

BARRIER THERAPEUTICS INC  
Form SC 13G/A  
February 17, 2009

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

SCHEDULE 13G

(Rule 13d-102)

INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT  
TO RULES 13d-1(b),(c), AND (d) AND AMENDMENTS THERETO FILED  
PURSUANT TO RULE 13d-2(b)

(Amendment No. 2)<sup>1</sup>

Barrier Therapeutics, Inc.  
(Name of Issuer)

Common Stock, \$.0001 par value  
(Title of Class of Securities)

06850R 10 8  
(CUSIP Number)

December 31, 2008  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

---

<sup>1</sup> The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

1.	Name of Reporting Person		
	I.R.S. Identification	Johnson & Johnson	
	No. of Above Person	22-1024240	
2.	(Entities Only) Check the Appropriate Box	(a) <input type="radio"/>	
3.	if a Member of a Group SEC Use Only	(b) <input type="radio"/>	
4.	Citizenship or Place of Organization	New Jersey	
	Number of	5. Sole Voting	0
	Shares Beneficially	Power	
	Owned by Each	6. Shared Voting	
	Reporting Person	Power	0
	With	7. Sole Dispositive	
		Power	0
		8. Shared Dispositive Power	
			0
9.	Aggregate Amount Beneficially Owned by Each Reporting Person		0
10.	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares		
		<input type="radio"/>	
11.	Percent of Class Represented by Amount in Row (9)		0
12.	Type of Reporting Person	CO	

1.	Name of Reporting Person		
	I.R.S. Identification		Johnson & Johnson Consumer Companies, Inc.
	No. of Above Person		
	(Entities Only)		
2.	Check the Appropriate Box	(a)	o
	if a Member of a Group	(b)	o
3.	SEC Use Only		
4.	Citizenship or Place		New Jersey
	of Organization		
	Number of	5.	Sole Voting Power
	Shares Beneficially		
	Owned by Each	6.	Shared Voting Power
	Reporting Person		
	With	7.	Sole Dispositive Power
		8.	Shared Dispositive Power
9.	Aggregate Amount Beneficially Owned by Each Reporting Person		0
10.	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares		
			o
11.	Percent of Class Represented by Amount in Row (9)		0
12.	Type of Reporting Person		CO

Edgar Filing: BARRIER THERAPEUTICS INC - Form SC 13G/A

CUSIP No. 06850R 10 8

Page 4 of 7 Pages

1.	Name of Reporting Person			
	I.R.S. Identification		Johnson & Johnson Development Corporation	
	No. of Above Person		22-2007137	
	(Entities Only)			
2.	Check the Appropriate Box	(a)	<input type="radio"/>	
	if a Member of a Group	(b)	<input type="radio"/>	
3.	SEC Use Only			
4.	Citizenship or Place		New Jersey	
	of Organization			
	Number of	5.	Sole Voting	0
	Shares Beneficially		Power	
	Owned by Each	6.	Shared Voting	
	Reporting Person		Power	0
	With	7.	Sole Dispositive	
			Power	0
		8.	Shared Dispositive Power	
				0
9.	Aggregate Amount Beneficially Owned			
	by Each Reporting Person			0
10.	Check Box if the Aggregate Amount in			
	Row (9) Excludes Certain Shares			
				<input type="radio"/>
11.	Percent of Class Represented by Amount			
	in Row (9)			0
12.	Type of Reporting Person		CO	

1.	Name of Reporting Person		
	I.R.S. Identification		Ortho-McNeil-Janssen Pharmaceuticals, Inc.
	No. of Above Person		
	(Entities Only)		
2.	Check the Appropriate Box	(a)	<input type="radio"/>
	if a Member of a Group	(b)	<input type="radio"/>
3.	SEC Use Only		
4.	Citizenship or Place		Delaware
	of Organization		
	Number of	5.	Sole Voting Power
	Shares Beneficially		0
	Owned by Each	6.	Shared Voting Power
	Reporting Person		0
	With	7.	Sole Dispositive Power
			0
		8.	Shared Dispositive Power
			0
9.	Aggregate Amount Beneficially Owned by Each Reporting Person		0
10.	Check Box if the Aggregate Amount in Row (9) Excludes Certain Shares		<input type="radio"/>
11.	Percent of Class Represented by Amount in Row (9)		0
12.	Type of Reporting Person		CO

Amendment No. 2 to Schedule 13G (Final Amendment)

Reference is hereby made to the statement on Schedule 13G originally filed with the Securities and Exchange Commission on February 8, 2005 and Amendment No. 1 thereto filed on February 9, 2006 (as so amended, the "Schedule 13G"). Terms defined in the Schedule 13G are used herein as so defined.

The following Items of the Schedule 13G are hereby amended and restated as follows:

ITEM 2(a) - NAME OF PERSON FILING:

Item 2(a) is hereby amended to reflect that Janssen Pharmaceutica Products, L.P. ("JPP") was dissolved on December 31, 2007 and its successor in interest is Ortho-McNeil-Janssen Pharmaceuticals, Inc. ("OMJP"), which is also a wholly-owned subsidiary of J&J, and is substituted for JPP herein as a Reporting Person.

ITEM 4 - OWNERSHIP:

Item 4 is hereby amended and restated to read in its entirety as follows:

(a) Amount Beneficially Owned:

J&J: 0 shares of Common Stock

JJDC: 0 shares of Common Stock

OMJP: 0 shares of Common Stock

JJCC: 0 shares of Common Stock

(b) Percent of Class:

J&J: 0

JJDC: 0

OMJP: 0

JJCC: 0

(c) Number of shares as to which such persons have:

(i) sole power to vote or to direct the vote: 0

(ii) shared power to vote or to direct the vote: 0

(iii) sole power to dispose or to direct the disposition of: 0

(iv) shared power to dispose or to direct the disposition of: 0

ITEM 5 - OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:

If this statement is being filed to report the fact that as of the date hereof the reporting persons have ceased to be the beneficial owners of more than five percent of the Common Stock, check the following X.



SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: February 14, 2009

JOHNSON & JOHNSON

By: /s/ Douglas Chia

Name: Douglas Chia

Title: Assistant Secretary

JOHNSON & JOHNSON DEVELOPMENT CORPORATION

By: /s/ Jayne Zall

Name: Jayne Zall

Title: Secretary

ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC.

By: Michael C. Chester

Name: Michael C. Chester

Title: Secretary

JOHNSON & JOHNSON CONSUMER COMPANIES, INC.

By: Clayton H. Paterson

Name: Clayton H. Paterson

Title: Secretary

-7-